Jason C Simeone1, Beth L Nordstrom1, Ketan Patel2, Alyssa B Klein3. 1. Real-World Evidence, Evidera, Waltham, MA 02451, USA. 2. Teradata UK Ltd, London, UK. 3. Oncology Business Unit, AstraZeneca, Gaithersburg, MD 20878, USA.
Abstract
Aim: To conduct a retrospective analysis of electronic medical record data to understand real-world treatment patterns and overall survival (OS) in patients with metastatic non-small-cell lung cancer (NSCLC). Materials & methods: We included n = 9656 adults (≥18 years) with metastatic NSCLC and no prior therapy. Data from 1 January 2013 to 31 January 2017 were analyzed. Results: Carboplatin plus paclitaxel was the most common first-line therapy (18.6%), and nivolumab was the most common second- (31.0%) and third-line (38.4%) therapy; 26.7% of all patients were untreated. Median OS from initial metastatic diagnosis was 11.1 months (95% CI: 10.8-11.5). Second-line immunotherapy extended OS by over 3 months versus second-line chemotherapy. Conclusion: Platinum-based therapy was the most common first-line therapy, and immunotherapy was the most common second- and third-line therapy. Median OS of patients with metastatic NSCLC was <1 year.
Aim: To conduct a retrospective analysis of electronic medical record data to understand real-world treatment patterns and overall survival (OS) in patients with metastatic non-small-cell lung cancer (NSCLC). Materials & methods: We included n = 9656 adults (≥18 years) with metastatic NSCLC and no prior therapy. Data from 1 January 2013 to 31 January 2017 were analyzed. Results:Carboplatin plus paclitaxel was the most common first-line therapy (18.6%), and nivolumab was the most common second- (31.0%) and third-line (38.4%) therapy; 26.7% of all patients were untreated. Median OS from initial metastatic diagnosis was 11.1 months (95% CI: 10.8-11.5). Second-line immunotherapy extended OS by over 3 months versus second-line chemotherapy. Conclusion:Platinum-based therapy was the most common first-line therapy, and immunotherapy was the most common second- and third-line therapy. Median OS of patients with metastatic NSCLC was <1 year.
Entities:
Keywords:
carcinoma; chemotherapy; electronic health records; immunotherapy; non-small-cell lung
Authors: Andrea Ardizzoni; Sergio Azevedo; Belen Rubio-Viqueira; Delvys Rodríguez-Abreu; Jorge Alatorre-Alexander; Hans J M Smit; Jinming Yu; Konstantinos Syrigos; Kerstin Trunzer; Hina Patel; Jonathan Tolson; Andres Cardona; Pablo D Perez-Moreno; Tom Newsom-Davis Journal: J Immunother Cancer Date: 2021-03 Impact factor: 13.751